TY - JOUR
T1 - Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD)
T2 - An observational study in Mexico [version 2; peer review: 1 approved]
AU - Maldonado-Arriaga, Brenda
AU - Sandoval-Jiménez, Sergio
AU - Rodríguez-Silverio, Juan
AU - Alcaráz-Estrada, Sofía Lizeth
AU - Cortés-Espinosa, Tomás
AU - de Vaca, Rebeca Pérez Cabeza
AU - Shaw, Jonathan
AU - Mondragón-Terán, Paul
AU - Hernández-Cortez, Cecilia
AU - Suárez-Cuenca, Juan Antonio
AU - Castro-Escarpulli, Graciela
N1 - Publisher Copyright:
© 2021. Maldonado-Arriaga B et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
PY - 2021
Y1 - 2021
N2 - Background: Fecal calprotectin (FC) can be a valuable tool to optimize health care for patients with inflammatory bowel disease (IBD). The objective of this observational study was to determine the level of knowledge of the FC test in Mexican patients with IBD. Methods: A self-report questionnaire was distributed via Facebook to patients with IBD. The survey consisted of 15 questions in two categories: the first category assessed knowledge of IBD diagnosis, Results: In total, 460 patients with IBD participated, of which 83.9% (386) had ulcerative colitis (UC) and 16.0% (74) had Crohn’s disease (CD). Regarding IBD diagnosis, 41.9% of participants stated that they did not know of a non-invasive test for fecal matter to identify inflammation of the colon. Regarding the FC test, 57.5% (UC) and 58.1% (CD) stated that they did not know about the test. Additionally, 65.8% (UC) and 51.3% (CD) of participants stated that they had never received the FC test and 82.6% (UC) and 77.0% (CD) recognized that the FC test was difficult to access in their medical practice. Furthermore, 66% (UC) and 52.7% (CD) of participants noted that their specialist doctor had never suggested the FC test to them, yet (UC) and 87.8% (CD) stated that they would prefer FC analysis for their IBD follow-up assessments. Conclusions: There is little knowledge of the FC biomarker among Mexican patients with IBD. This suggests the need for greater dissemination of its use and scope as a biomarker in IBD.
AB - Background: Fecal calprotectin (FC) can be a valuable tool to optimize health care for patients with inflammatory bowel disease (IBD). The objective of this observational study was to determine the level of knowledge of the FC test in Mexican patients with IBD. Methods: A self-report questionnaire was distributed via Facebook to patients with IBD. The survey consisted of 15 questions in two categories: the first category assessed knowledge of IBD diagnosis, Results: In total, 460 patients with IBD participated, of which 83.9% (386) had ulcerative colitis (UC) and 16.0% (74) had Crohn’s disease (CD). Regarding IBD diagnosis, 41.9% of participants stated that they did not know of a non-invasive test for fecal matter to identify inflammation of the colon. Regarding the FC test, 57.5% (UC) and 58.1% (CD) stated that they did not know about the test. Additionally, 65.8% (UC) and 51.3% (CD) of participants stated that they had never received the FC test and 82.6% (UC) and 77.0% (CD) recognized that the FC test was difficult to access in their medical practice. Furthermore, 66% (UC) and 52.7% (CD) of participants noted that their specialist doctor had never suggested the FC test to them, yet (UC) and 87.8% (CD) stated that they would prefer FC analysis for their IBD follow-up assessments. Conclusions: There is little knowledge of the FC biomarker among Mexican patients with IBD. This suggests the need for greater dissemination of its use and scope as a biomarker in IBD.
KW - Crohn’s disease
KW - Fecal calprotectin
KW - Inflammatory bowel disease
KW - Level of knowledge
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85117323354&partnerID=8YFLogxK
U2 - 10.12688/F1000RESEARCH.27629.2
DO - 10.12688/F1000RESEARCH.27629.2
M3 - Artículo
AN - SCOPUS:85117323354
SN - 2046-1402
VL - 9
SP - 1
EP - 17
JO - F1000Research
JF - F1000Research
ER -